Avenue Therapeutics, Inc. (ATXI)
| Market Cap | 988.49K -50.4% |
| Revenue (ttm) | 1.40M |
| Net Income | -1.75M |
| EPS | -0.55 |
| Shares Out | 3.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 404 |
| Average Volume | 4,861 |
| Open | 0.2710 |
| Previous Close | 0.3000 |
| Day's Range | 0.2710 - 0.3098 |
| 52-Week Range | 0.1500 - 0.9699 |
| Beta | -0.08 |
| RSI | 36.75 |
| Earnings Date | May 20, 2026 |
About Avenue Therapeutics
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York. [Read more]
Financial Performance
Financial StatementsNews
Avenue Therapeutics enters worldwide license agreement for ATX-04
Avenue Therapeutics (ATXI) announced that it has entered into an exclusive worldwide license agreement with Duke University for patents and know-how pertaining to ATX-04 in clinical development for th...
Avenue Therapeutics Transcript: AGM 2025
The 2025 Annual Meeting confirmed a quorum, elected all nominated directors for the next term, and ratified KPMG LLP as the independent auditor for 2025. Stockholders were invited to submit questions for follow-up after the meeting.
Avenue Therapeutics announces Baergic Bio acquisition by Axsome
Avenue Therapeutics (ATXI) subsidiary, Baergic Bio announced that Avenue has entered into an agreement for Baergic to be acquired by Axsome Therapeutics (AXSM), including the global rights to BAER-101...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Annexon (ANNX), 807% surge in interest Avenue Therapeutic...
Avenue Therapeutics files $35M mixed securities shelf
17:16 EST Avenue Therapeutics (ATXI) files $35M mixed securities shelf
Avenue Therapeutics reports Q3 EPS $(1.92) , consensus (94c)
As of September 30 cash and cash equivalents totaled $2.6M , compared to $4.9M at June 30 and $1.8 M at December 31, 2023, a decrease of $2.3M compared to…
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
- Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy anticipated around year-end 2024 - Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulba...
Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit
MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...
Avenue Therapeutics to Participate in Upcoming Investor Conferences
MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of t...
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
- Last patient visit complete in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data anticipated in second half of 2024 –
Avenue Therapeutics Transcript: AGM 2024
The meeting confirmed a quorum, approved the election of directors, ratified KPMG LLP as auditors for 2024, and passed an amendment to the 2015 Incentive Plan increasing authorized shares and extending its term. Attendees could submit questions online.
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Topline results of the Phase 1b/2a clinical trial anticipated mid-year 2024 Topline results of the Phase 1b/2a clinical trial anticipated mid-year 2024
Avenue Therapeutics reports Q1 EPS ($15.40) vs ($101.57) last year
“The first quarter was incredibly productive for Avenue, as we’ve successfully executed on key milestones across our pipeline of CNS treatments,” said Alexandra MacLean, M.D., Chief Executive Officer ...
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or...
Avenue Therapeutics files to sell 1.42M shares of common stock for holders
06:13 EDT Avenue Therapeutics files to sell 1.42M shares of common stock for holders
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of t...
Avenue Therapeutics trading resumes
09:51 EDT Avenue Therapeutics trading resumes
Avenue Therapeutics trading halted, volatility trading pause
09:41 EDT Avenue Therapeutics trading halted, volatility trading pause
Avenue Therapeutics trading halted, news pending
19:50 EDT Avenue Therapeutics trading halted, news pending
Avenue Therapeutics announces 1-for-75 reverse stock split
Avenue Therapeutics announced that it will effect a 1-for-75 reverse split of its issued and outstanding common stock. Avenue expects its common stock to begin trading on a split-adjusted basis…
Avenue Therapeutics Announces Reverse Stock Split
MIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of t...
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of t...
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 -
Avenue Therapeutics granted extension for Nasdaq compliance
Avenue Therapeutics announced that by decision dated March 11, 2024, the Nasdaq Hearings Panel granted the Company’s request for an extension to evidence compliance with all applicable criteria for co...